FigureĀ 1.
Clinical outcomes after allogeneic HSCT according to the presence or absence of letermovir prophylaxis. (A) Cumulative incidence of csCMVi, (B) OS, (C) CIR, and (D) NRM in patients with letermovir prophylaxis (blue, dotted line) or without cytomegalovirus prophylaxis (red, solid line).